Patent issued to RegeneRx for treatment of biological toxins

RegeneRx Pharmaceuticals, Inc., announced on December 1 that it has received a patent in Australia for a technique to use thymosin beta 4 and various fragments and analogues of TB4 to prevent and treat biological immune responses to reactive biological, chemical and toxic agents.

RegeneRx has patent claims pending in several other countries, including the U.S. The Australian patent will expire in 2024.

TB4 is at the center of RegenRx’s research, and the company is using it to develop means of tissue and organ protection, repair and regeneration. The Rockville, Marylan-based company has three drug candidates that are currently in clinical development and holds patents in several countries.

RegenRx is best known for its development of RGN-352, an injectable formulation meant to treat cardiovascular and central nervous system diseases. RGN-352 is initially targeting patients that have suffered an acute myocardial infarction, but research suggests that it could also be used for those with multiple sclerosis, stroke and traumatic brain injury.

The company recently received $730,000 in funding under the Patient Protection and Affordable Care Act in order to support all three of its product candidates.

The company's newest patent covers allergic reactions, such as contact dermatitis, poison ivy and insect bites, as well as skin indications like psoriasis and eczema.